Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Background: Available therapies for myelofibrosis may exacerbate cytopenias and are not indicated for patients with severe thrombocytopenia. The JAK2/FLT3 inhibitor pacritinib induced spleen responses with limited myelosuppression in phase 1/2 trials. We aimed to assess the efficacy and safety of pa...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Mesa, R, Vannucchi, A, Mead, A, Egyed, M, Szoke, A, Suvorov, A, Jakucs, J, Perkins, A, Prasad, R, Mayer, J, Demeter, J, Ganly, P, Singer, J, Zhou, H, Dean, J, te Boekhorst, P, Nangalia, J, Kiladjian, J, Harrison, C
Định dạng: Journal article
Được phát hành: Lancet 2017

Những quyển sách tương tự